Analyst Ratings for Guardant Health (GH)
GH Rating Summary
GH Price Target Summary
- Highest: $225.00 (UBS)
- Lowest: $80.00 (Nephron)
- Average: $185.04
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$185.04 (+16.7%)
* Over Last 12-Mos
Rating Score: 9.1 / 10
Percentile Rank: 89%
Rating Score: 9.1 / 10
Percentile Rank: 89%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/9/2026 | UBS | Douglas Schenkel | New Coverage | Buy (N/A) |
225.00 (N/A) |
160.98 (158.60) |
-1.48% | Details |
| 9/8/2026 | Rothschild Redburn | Jamie Clark | New Coverage | Buy (N/A) |
203.00 (N/A) |
161.04 (158.60) |
-1.52% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
